Koersdaling vrijdag is zoals eerder aangegeven deels door stoplosses getriggerd, maar de biotech index is ook stevig gezakt vrijdag met iets van 6 %.
The Nasdaq Biotech Index (.NBI) was down 6.2 percent, led lower by a 5.6 percent drop in Celgene.
The biotech index is on track for a 14-percent loss for the week.
Abbvie daalde vrijdag ook met 1.5% en Vertex met 7%.en Celgene met 5%.
De berichtgeving van ABBVIE dat zij hun eigen JAK1 gaan ontvwikkelen lijkt haar koersval iets te hebben getemperd.
Op Yahoo staat het volgende:
7:16 am AbbVie will not exercise its right to in-license the Galapagos (GLPG) JAK1 inhibitor, filgotinib (ABBV) :
The co announced that it will advance ABT-494, its internally developed investigational selective JAK1 inhibitor, to Phase 3 studies in rheumatoid arthritis.
Following a thorough review of available data, AbbVie will not exercise its right to in-license the Galapagos (GLPG) JAK1 inhibitor, filgotinib. Per the terms of the agreement with Galapagos, all rights to filgotinib will revert solely to Galapagos.
7:14 am AbbVie announces results from two Phase 2 clinical trials evaluating its JAK1 inhibitor, ABT-494, in patients with inadequate response to either methotrexate or TNF inhibitors, meets primary endpoint in both studies (ABBV) :
The clinical trials, BALANCE-I and BALANCE-II, achieved ACR20 at week 12 across all dose levels, except the lowest dose in BALANCE-II. BALANCE-I and BALANCE-II evaluated patients with moderate to severe rheumatoid arthritis with inadequate responses to prior anti-TNF (TNF-IR) or methotrexate (MTX-IR) treatment, respectively. Overall rates of discontinuation and serious adverse events were reported in two patients, one on placebo and one on ABT-494. The most common adverse event was headache, which occurred in less than 5% of ABT-494 treated patients.
In the TNF-inadequate responder population, ACR20 responses up to 73 percent and ACR50 responses up to 44 percent
In the MTX-inadequate responder population, ACR20 responses up to 82 percent and ACR50 responses up to 50 percent
"We are encouraged by the results of our Phase 2 studies and we will advance ABT-494 to Phase 3 studies with a once-daily formulation."